Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toluene SCHEMBL28191452 | 0.91 | RAB9A (0.56) | RAB9ARXFP1MAPTKMT2AKDM4E | |
| SCHEMBL7203836 | 0.87 | RAB9A (0.60) | RAB9ARXFP1MAPTKMT2AKDM4E | |
| SCHEMBL28471002 | 0.86 | MAOB (0.49) | RAB9ARXFP1MAPTKMT2AKDM4E | |
| SCHEMBL11632216 | 0.86 | RAB9A (0.62) | RAB9ARXFP1MAPTKMT2AKDM4E | |
| SCHEMBL14774895 | 0.85 | TSHR (0.51) | RAB9ARXFP1MAPTKMT2AKDM4E | |
| SCHEMBL1493670 | 0.84 | KMT2A (0.60) | RAB9ARXFP1MAPTKMT2AKDM4E | |
| SCHEMBL3719794 | 0.84 | MAOB (0.63) | RAB9ARXFP1MAPTKMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL11632213 | 0.84 | RAB9A (0.61) | RAB9ARXFP1MAPTKMT2AKDM4E | |
| SCHEMBL28145792 | 0.82 | RAB9A (0.62) | RAB9ARXFP1MAPTKMT2AKDM4E | |
| SCHEMBL9677464 | 0.81 | LMNA (0.48) | KMT2AALDH1A1MAOBF2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112566894-B | Potent inhibitors of D-amino acid oxidase (DAAO) and uses thereof | 心悦生医股份有限公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-117964628-A | Macrocyclic compounds as CDK9 inhibitors and application thereof | 科辉智药生物科技(深圳)有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-114945572-A | HBF pharmacological inducing compounds for the treatment of sickle cell anemia and beta-thalassemia | 刘扶东 | 2022-08-26 | — | — | CN | disclosed |
| CN-114929672-A | Cancer therapy targeting cancer stem cells | 治疗方案股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-114746095-A | HCK as therapeutic target of MYD88 mutant disease | 达纳-法伯癌症研究所有限公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-114727974-A | HDAC6 inhibitors and uses thereof | 艾科尼佐治疗股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-113557017-A | Inhibitors of cyclin-dependent kinase 7 and uses thereof | 达纳-法伯癌症研究所股份有限公司 | 2021-10-26 | — | — | CN | disclosed |
| CN-107530329-B | Pyrazolo [1, 5-a ] [1, 3, 5] triazine and pyrazolo [1, 5-a ] pyrimidine derivatives as CDK inhibitors | 奥瑞基尼探索技术有限公司 | 2021-10-08 | — | — | CN | disclosed |
| CN-113278617-A | Chiral design | 波涛生命科学有限公司 | 2021-08-20 | — | — | CN | disclosed |
| CN-106068325-B | Chiral design | 波涛生命科学有限公司 | 2021-07-09 | — | — | CN | disclosed |
| US-7119188-B2 | N-carbobenzyloxy (N-CBZ)-deprotecting enzyme and uses therefor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-10 | — | — | US | disclosed |
| US-20060149047-A1 | N-CARBOBENZYLOXY (N-CBZ)-DEPROTECTING ENZYME AND USES THEREFOR | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-06 | — | — | US | disclosed |
| EP-1629087-A2 | N-CARBOBENZYLOXY (N-CBZ)-DEPROTECTING ENZYME AND USES THEREFOR | Bristol-Myers Squibb Company (US) | 2006-03-01 | — | — | EP | disclosed |
| WO-2005001047-A2 | N-CARBOBENZYLOXY (N-CBZ)-DEPROTECTING ENZYME AND USES THEREFOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-06 | — | — | WO | disclosed |
| US-6828119-B2 | Deprotecting a hydroxide or amine; obtain sample, incubate with enzyme, remoe protecting group, recover amine | BRISTOL MYERS SQUIBB COMPANY | 2004-12-07 | — | — | US | disclosed |
| EP-1348025-A2 | ENZYMATIC DEPROTECTION OF AMINES AND HYDROXIDES | Bristol-Myers Squibb Company (US) | 2003-10-01 | — | — | EP | disclosed |
| EP-1294716-A1 | LACTAM INHIBITORS OF FACTOR XA AND METHOD | Bristol-Myers Squibb Company (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20020123110-A1 | Enzymatic deprotection of amines and hydroxides | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-05 | — | — | US | disclosed |
| WO-2002053724-A2 | ENZYMATIC DEPROTECTION OF AMINES AND HYDROXIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-07-11 | — | — | WO | disclosed |
| WO-2001096331-A1 | LACTAM INHIBITORS OF FACTOR XA AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149047-A1 | N-CARBOBENZYLOXY (N-CBZ)-DEPROTECTING ENZYME AND USES THEREFOR | CMBL, BCHE, NOTUM | RAB9A 4126/4885RXFP1 3933/4885MAPT 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.